Skip to main content
Premium Trial:

Request an Annual Quote

Shimadzu Launches Biotech Unit to Sell Genomics, Proteomics Tools

NEW YORK, March 21 – Shimadzu of Kyoto, Japan has launched a new global business unit that will focus on selling DNA sequencing and mass spectrometry products, the company said Wednesday.

The unit’s product portfolio will build on the AXIMA MALDI-TOF and MALDI-IT TOF quadruple ion trap mass spectrometry technology developed by the company’s subsidiary Kratos Analytical. Kratos is developing DNA and SNP analysis applications for these products as well as combinatorial chemistry applications.

The business unit will also build upon the proteomics alliance established in mid-2000 between Shimadzu and Proteome Systems of Sydney, Australia and Boston. The companies have said they would establish joint proteomics facilities in Sydney and Boston, using Kratos’ MALDI-TOF mass spectrometers and would jointly develop new proteomics tools that will help to automate protein analysis.

Tetsuo Ichikawa, who has up until now served as life sciences head for Shimadzu, a 125 year-old scientific instrument maker, will serve as head of this business unit.

"We see an excellent strategic fit between our know-how and the critical success factors that will be essential to the future of the biotech industry,” Ichikawa said in a statement. “Shimadzu Biotech is our solution to guaranteeing that we can deliver this expertise to the sector."

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.